NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
5/8 — Partial
NAMENDA XR (memantine hydrochloride) by AbbVie is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer's disease. First approved in 2010.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAMENDA XR is an extended-release oral capsule formulation of memantine hydrochloride, a low-to-moderate affinity NMDA receptor antagonist approved for Alzheimer's disease. It works by blocking excessive glutamate signaling at NMDA receptors to reduce cognitive decline symptoms, though it does not prevent or slow neurodegeneration. The XR formulation enables once-daily dosing for improved patient compliance.
$0.002BPart D
Peak3.3 years to LOEProduct is at peak lifecycle stage with stable but modest Part D spending; moderate competitive pressure suggests team focus is on retention and optimization rather than rapid growth.
Mechanism of Action
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
Started Jun 2013
3,482 enrolled
Alzheimer's Desease
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Started Jul 2008
42 enrolled
Down Syndrome
Why This Matters for Your Career
Worked on NAMENDA XR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.